Paris and Villejuif, France – March, the 2st 2016

Sanofi and Gustave Roussy strengthen their translational research collaboration in oncology

This agreement is aimed to promote personalized medicine and the development of new molecules for cancer patient

Sanofi and Gustave Roussy, the leading cancer centre in Europe, announced today that they will continue their clinical and scientific collaboration which began in 2012, strengthening their partnership in oncology research. The objective is to promote personalized medicine and collaborative projects in translational research and thus accelerate the development of new molecules and the evaluation of these molecules in cancer patients.

The agreement between Sanofi and Gustave Roussy has been renewed for a period of three years. It will reinforce the teams' joint experience in early therapeutic development and will enable to promote collaborations in the field of immuno-oncology and immunoconjugates (antibodies conjugated to a powerful toxic agent).
Sanofi will continue to make it possible for Gustave Roussy – and its DITEP (Département d’Innovation Thérapeutique et Essais Précoces – Department of Therapeutic Innovation and Early Trials) in particular – to participate in its phase I/II trials set up in Europe.

« We are pleased with the first four years of collaboration with Gustave Roussy. Together we have advanced the translational research for the benefit of our most promising programmes and above all, many patients have been able to benefit from innovative and better targeted molecules », said Marc Bonnefoi, Vice President R&D France, Sanofi.

To improve the evaluation of new molecules at an early stage of their development, the Sanofi and Gustave Roussy teams have particularly developed the translational segment as regards the MOSCATO (MOlecular Screening for CAncer Treatment Optimisation) biomedical research programme promoted by Gustave Roussy and carried out by the DITEP since 2011. The main objective is to better characterise the patient populations targeted in the development of molecules from Sanofi portfolio, and to identify and validate biomarkers enabling to support their development.
This collaboration should make it possible to accelerate the development of innovative molecules, better adapted to patients and their tumor characteristics and thus offer to clinicians new therapeutic solutions for the greatest benefit of patients.

 « Sanofi was an important partner in the MOSCATO-01 study. Being able to establish the molecular profiles of tumours in routine clinical practice makes it possible to direct patients towards the targeted therapies that are best suited, and potentially the most effective, for their situations. The analysis that we are currently conducting on over a thousand patients that benefited from this personalized medicine strategy is expected to confirm the relevance of such an approach to patient benefit », said Professor Jean-Charles Soria, Head of the DITEP at Gustave Roussy.

A second phase of the programme (MOSCATO-02 study) will be initiated in 2016, introducing, into patient molecular profiles, the characterisation of immunological biomarkers which may provide patients greater access to new immunotherapies in development.

About the personalized medicine in oncology

The personalized medicine is currently experiencing a significant expansion in oncology and is opening the pathway to new and promising perspectives for patients, with greater therapeutic efficacy in order to avoid useless or toxic treatments. It makes it possible to improve patient care based on the molecular characterisation of their tumours (genetic and biological characteristics). These criteria are now taken into account in the choice of treatment – a choice which is no longer made solely based on the type and stage of the cancer.

About the DITEP

The only facility of its kind in France, the DITEP (Département d’Innovation Thérapeutique et Essais Précoces – Department of Therapeutic Innovation and Early Trials) embodies, develops and promotes clinical research as an act of care, based on providing the greatest number of patients with access to therapeutic innovation and early trials. Founded in September 2013 and directed by Professor Jean-Charles Soria, this department is currently the most advanced phase I/II centre in Europe. An essential partner in early trials, this department makes it possible to integrate patient care into a transversal and multidisciplinary framework.
Entirely dedicated to early trials and molecular and immunological characterisation of tumours in patients with advanced metastatic cancer, the DITEP cared for more than 900 patients in 2015. 440 of these patients were included in an early trial in cancerology, and nearly 500 were included in a precision medicine programme making it possible to determine the best therapeutic options for each patient.

Icône PDF > Read the press release in PDF

Catégorie de la page: